Company intelligence / Profile preview

Vaxil Bio Ltd.

Ownership: Private
Development stage: Phase 1

Overview

Lead product ImMucin™ completed Phase 1/2 clinical trial in multiple myeloma patients and received orphan drug status from FDA and EMA. The company is currently evaluating whether to continue development or pursue other business opportunities.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Peptide vaccinesmonoclonal antibodies (mAbs)signal peptide-based immunotherapies
Industry: Biotech

Drug pipeline

7 assets

MUC1 vaccine

6 more assets in the full pipeline.

Request access →

Partnerships

BGN Technologies (licensed E-selectin targeting technology)

Beyond the preview

Go deeper on Vaxil Bio Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxil Bio Ltd..

Explore the full profile